Droxidopa — 100MG, Capsule, bottle of 90 capsules

Droxidopa — 100MG, Capsule, bottle of 90 capsules

Droxidopa is a capsule for oral use. Droxidopa capsules are indicated for the treatment of orthostatic dizziness, lightheadedness, or the “feeling that you are about to black out” in adult patients with symptomatic neurogenic orthostatic hypotension (nOH) caused by primary autonomic failure (Parkinson's disease [PD], multiple system atrophy, and pure autonomic failure), dopamine beta-hydroxylase deficiency, and non-diabetic autonomic neuropathy. Effectiveness beyond 2 weeks of treatment has not been established.

• Active ingredient or product type: DROXIDOPA
• Strength/concentration: 100MG
• Dosage form and route: Capsule, Oral
• Exact package presentation: bottle of 90 capsules
• NDC/item number: 31722-014-90
• Manufacturer: CAMBER PHARMACEUTICALS
• Storage/handling: stored at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].
• Status: Rx only

Important safety information: • Droxidopa capsules may cause supine hypertension and may increase cardiovascular risk if supine hypertension is not well-managed ( 5.1 ) • Hyperpyrexia and confusion ( 5.2 ) • May exacerbate symptoms in patients with existing ischemic heart disease, arrhythmias, and congestive heart failure ( 5.3 ) • Allergic reactions ( 5.4 ) 5.1 Supine Hypertension Droxidopa capsules are therapy may cause or exacerbate supine hypertension in patients with nOH.

Refer to the current product labeling for complete indications, preparation or administration instructions, contraindications, warnings, precautions, and storage requirements.